{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:20:10Z","timestamp":1741238410597,"version":"3.38.0"},"reference-count":64,"publisher":"JLE","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie &amp; Th\u00e9rapeutique"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.nephro.2018.09.002","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T12:45:13Z","timestamp":1538829913000},"page":"484-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toxicit\u00e9 r\u00e9nale des produits de contraste non iod\u00e9s"],"prefix":"10.1684","volume":"14","author":[{"given":"Nicolas","family":"Janus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Launay-Vacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"Deray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2018.09.002_bib0325","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ctrv.2011.05.001","article-title":"Importance of monitoring renal function in patients with cancer","volume":"38","author":"Aapro","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.nephro.2018.09.002_bib0330","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40261-013-0066-0","article-title":"Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children","volume":"33","author":"Scott","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.nephro.2018.09.002_bib0335","series-title":"Guide de prescription des m\u00e9dicaments chez le patient insuffisant r\u00e9nal","article-title":"GPR Produits de contraste","author":"Amet","year":"2010"},{"key":"10.1016\/j.nephro.2018.09.002_bib0340","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/jmri.21967","article-title":"Role of thermodynamic and kinetic parameters in gadolinium chelate stability","volume":"30","author":"Id\u00e9e","year":"2009","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.nephro.2018.09.002_bib0345","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/00004424-199907000-00001","article-title":"Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment","volume":"34","author":"Swan","year":"1999","journal-title":"Invest Radiol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0350","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/(SICI)1522-2586(199902)9:2<317::AID-JMRI25>3.0.CO;2-B","article-title":"Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function","volume":"9","author":"Swan","year":"1999","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.nephro.2018.09.002_bib0355","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1007\/s00330-002-1629-2","article-title":"Dialysis and contrast media","volume":"12","author":"Morcos","year":"2002","journal-title":"Eur Radiol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0360","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/ACI.0b013e32834877c3","article-title":"Anaphylaxis to radiographic contrast media","volume":"11","author":"Brockow","year":"2011","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0365","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2214\/AJR.07.2554","article-title":"Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults","volume":"189","author":"Dillman","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0370","doi-asserted-by":"crossref","first-page":"W138","DOI":"10.2214\/AJR.10.4885","article-title":"Incidence of immediate gadolinium contrast media reactions","volume":"196","author":"Prince","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0375","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00261-001-0186-5","article-title":"European Society of Urogenital Radiology European Society of Urogenital Radiology guidelines on administering contrast media","volume":"28","author":"Morcos","year":"2003","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.nephro.2018.09.002_bib0380","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.2215\/CJN.02070606","article-title":"Defining acute renal failure: RIFLE and beyond","volume":"1","author":"Van Biesen","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0385","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1148\/radiology.218.3.r01mr12651","article-title":"Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study","volume":"218","author":"Tombach","year":"2001","journal-title":"Radiology"},{"key":"10.1016\/j.nephro.2018.09.002_bib0390","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0730-725X(92)90380-I","article-title":"Gd-DOTA: evaluation of its renal tolerance in patients with chronic renal failure","volume":"10","author":"Bellin","year":"1992","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.nephro.2018.09.002_bib0395","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/ndt\/17.5.824","article-title":"Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function","volume":"17","author":"Rieger","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.09.002_bib0400","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2215\/CJN.06011108","article-title":"Current status of gadolinium toxicity in patients with kidney disease","volume":"4","author":"Perazella","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0405","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1148\/radiol.2503080253","article-title":"Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency","volume":"250","author":"Ledneva","year":"2009","journal-title":"Radiology"},{"key":"10.1016\/j.nephro.2018.09.002_bib0410","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ccd.22907","article-title":"The use of gadolinium in patients with contrast allergy or renal failure requiring coronary angiography, coronary intervention, or vascular procedure","volume":"78","author":"Saleh","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.nephro.2018.09.002_bib0415","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0741-5214(03)00315-X","article-title":"Safety of gadolinium contrast angiography in patients with chronic renal insufficiency","volume":"38","author":"Sam","year":"2003","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.nephro.2018.09.002_bib0420","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/ndt\/gfi304","article-title":"The safety of gadolinium in patients with stage 3\u00a0and 4\u00a0renal failure","volume":"21","author":"Erg\u00fcn","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.09.002_bib0425","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1007\/s00330-004-2379-0","article-title":"Gadolinium-based contrast media may be nephrotoxic even at approved doses","volume":"14","author":"Thomsen","year":"2004","journal-title":"Eur Radiol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0430","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0221-0363(09)72502-8","article-title":"What are the remaining indications for gadolinium contrast in CT","volume":"90","author":"Cl\u00e9ment","year":"2009","journal-title":"J Radiol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0435","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1038\/sj.ki.5000369","article-title":"Prevention of contrast-induced nephropathy with volume supplementation","volume":"100","author":"Mueller","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.09.002_bib0440","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1684\/bdc.2011.1477","article-title":"Renal toxicity of contrast agents in oncologic patients","volume":"99","author":"Amet","year":"2012","journal-title":"Bull Cancer"},{"year":"2004","series-title":"Pr\u00e9vention de l\u2019insuffisance r\u00e9nale induite par les produits de contraste iod\u00e9s","author":"Cl\u00e9ment","key":"10.1016\/j.nephro.2018.09.002_bib0445"},{"key":"10.1016\/j.nephro.2018.09.002_bib0450","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(00)02694-5","article-title":"Scleromyxoedema-like cutaneous diseases in renal-dialysis patients","volume":"356","author":"Cowper","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2018.09.002_bib0455","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00000372-200110000-00001","article-title":"Nephrogenic fibrosing dermopathy","volume":"23","author":"Cowper","year":"2001","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0460","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.revmed.2009.07.023","article-title":"Nephrogenic systemic fibrosis","volume":"32","author":"Franc\u00e8s","year":"2011","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.nephro.2018.09.002_bib0465","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.semarthrit.2005.08.002","article-title":"Description of 12\u00a0cases of nephrogenic fibrosing dermopathy and review of the literature","volume":"35","author":"Mendoza","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.nephro.2018.09.002_bib0470","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1684\/stv.2009.0455","article-title":"Toxicit\u00e9 des ch\u00e9lates de gadolinium chez le patient insuffisant r\u00e9nal","volume":"22","author":"Ledneva","year":"2010","journal-title":"Sang Thromb Vaiss"},{"key":"10.1016\/j.nephro.2018.09.002_bib0475","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.jaad.2005.04.024","article-title":"Nephrogenic fibrosing dermopathy\/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure","volume":"54","author":"Kucher","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0480","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archderm.139.7.903","article-title":"Nephrogenic fibrosing dermopathy with systemic involvement","volume":"139","author":"Ting","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0485","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.ajkd.2005.08.008","article-title":"Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy","volume":"46","author":"Cowper","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2018.09.002_bib0490","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1681\/ASN.2006060601","article-title":"Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging","volume":"17","author":"Marckmann","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2010.08.041","article-title":"Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations","volume":"65","author":"Girardi","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0500","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/MNH.0b013e3282f4b605","article-title":"Nephrogenic systemic fibrosis: epidemiology update","volume":"17","author":"Marckmann","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.nephro.2018.09.002_bib0505","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/art.22925","article-title":"Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure","volume":"56","author":"Todd","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nephro.2018.09.002_bib0510","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/ndt\/gfq693","article-title":"Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature","volume":"26","author":"Cuffy","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.09.002_bib0515","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaad.2009.03.040","article-title":"Nephrogenic systemic fibrosis \u2013 a rapidly progressive disabling disease with limited therapeutic options","volume":"61","author":"Schieren","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0520","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/jca.20170","article-title":"Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy\/nephrogenic systemic fibrosis: three case reports and review of literature","volume":"23","author":"Mathur","year":"2008","journal-title":"J Clin Apher"},{"key":"10.1016\/j.nephro.2018.09.002_bib0525","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1002\/art.23696","article-title":"Imatinib mesylate treatment of nephrogenic systemic fibrosis","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nephro.2018.09.002_bib0530","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1525-139X.2007.00399.x","article-title":"Nephrogenic systemic fibrosis: early recognition and treatment","volume":"21","author":"Knopp","year":"2008","journal-title":"Semin Dial"},{"key":"10.1016\/j.nephro.2018.09.002_bib0535","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jaad.2009.04.022","article-title":"Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: possible role of phospho-70-ribosomal-S6\u00a0kinase","volume":"62","author":"Swaminathan","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0540","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2340\/00015555-1085","article-title":"Positive effect of low-dose imatinib mesylate in a patient with nephrogenic systemic fibrosis","volume":"91","author":"Elmholdt","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0545","first-page":"922","article-title":"Alefacept therapy for nephrogenic systemic fibrosis: a case series","volume":"10","author":"Robinson","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000149628","article-title":"Nephrogenic systemic fibrosis","volume":"29","author":"Nainani","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0555","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jaad.2009.10.038","article-title":"Revisiting nephrogenic systemic fibrosis in 6\u00a0kidney transplant recipients: a single-center experience","volume":"63","author":"Lemy","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0560","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1148\/radiol.2431062144","article-title":"Nephrogenic systemic fibrosis: risk factors and incidence estimation","volume":"243","author":"Sadowski","year":"2007","journal-title":"Radiology"},{"key":"10.1016\/j.nephro.2018.09.002_bib0565","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1067\/S0022-3476(03)00538-9","article-title":"Nephrogenic fibrosing dermopathy: two pediatric cases","volume":"143","author":"Jan","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.nephro.2018.09.002_bib0570","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.jcmg.2011.08.013","article-title":"Nephrogenic systemic fibrosis: review of 370\u00a0biopsy-confirmed cases","volume":"4","author":"Zou","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.nephro.2018.09.002_bib0575","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/0003-4819-145-3-200608010-00021","article-title":"Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy","volume":"145","author":"Swaminathan","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2018.09.002_bib0580","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2214\/AJR.08.1541","article-title":"Nephrogenic systemic fibrosis: some considerations on the debate regarding its cause","volume":"191","author":"Provenzale","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0585","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejrad.2008.01.032","article-title":"An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital","volume":"66","author":"Marckmann","year":"2008","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0590","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/ndt\/gfk062","article-title":"Gadolinium \u2013 a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?","volume":"21","author":"Grobner","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.09.002_bib0595","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaad.2006.10.047","article-title":"Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis","volume":"56","author":"High","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0600","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1259\/bjr\/17111243","article-title":"Nephrogenic systemic fibrosis following the administration of extracellular gadolinium-based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?","volume":"80","author":"Morcos","year":"2007","journal-title":"Br J Radiol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0605","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MOU.0b013e328011c96f","article-title":"European Society of Urogenital Radiology European Society of Urogenital Radiology guidelines on contrast media application","volume":"17","author":"Thomsen","year":"2007","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0610","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2215\/CJN.00030107","article-title":"Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link?","volume":"2","author":"Perazella","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0615","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1472-8206.2006.00447.x","article-title":"Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review","volume":"20","author":"Id\u00e9e","year":"2006","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0620","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejrad.2008.11.021","article-title":"Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study","volume":"73","author":"Janus","year":"2010","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0625","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/RLI.0000000000000000","article-title":"Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrog\u00e9nique Syst\u00e9mique study","volume":"49","author":"Amet","year":"2014","journal-title":"Invest Radiol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0630","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jradio.2011.02.017","article-title":"Kidney and iodinated and gadolinium-based contrast agents","volume":"92","author":"Cl\u00e9ment","year":"2011","journal-title":"J Radiol"},{"key":"10.1016\/j.nephro.2018.09.002_bib0635","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/jmri.21981","article-title":"Removal of gadolinium by dialysis: review of different strategies and techniques","volume":"30","author":"Silberzweig","year":"2009","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.nephro.2018.09.002_bib0320","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/jmri.21968","article-title":"Nephrogenic systemic fibrosis versus contrast-induced nephropathy: risks and benefits of contrast-enhanced MR and CT in renally impaired patients","volume":"30","author":"Martin","year":"2009","journal-title":"J Magn Reson Imaging"}],"container-title":["N\u00e9phrologie &amp; Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S176972551830587X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S176972551830587X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2018.09.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T14:34:16Z","timestamp":1741185256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S176972551830587X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S176972551830587X"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2018.09.002","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicit\u00e9 r\u00e9nale des produits de contraste non iod\u00e9s","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2018.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation.","name":"copyright","label":"Copyright"}]}}